Cargando…

Serum levels of irisin and nesfatin-1 in multiple sclerosis

BACKGROUND: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. OBJECTIVE: The present study is a preli...

Descripción completa

Detalles Bibliográficos
Autores principales: ALTAŞ, Mustafa, UCA, Ali Ulvi, AKDAĞ, Turan, ODABAŞ, Faruk Ömer, TOKGÖZ, Osman Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academia Brasileira de Neurologia -ABNEURO 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648912/
https://www.ncbi.nlm.nih.gov/pubmed/35195223
http://dx.doi.org/10.1590/0004-282X-ANP-2020-0520
_version_ 1784827682823864320
author ALTAŞ, Mustafa
UCA, Ali Ulvi
AKDAĞ, Turan
ODABAŞ, Faruk Ömer
TOKGÖZ, Osman Serhat
author_facet ALTAŞ, Mustafa
UCA, Ali Ulvi
AKDAĞ, Turan
ODABAŞ, Faruk Ömer
TOKGÖZ, Osman Serhat
author_sort ALTAŞ, Mustafa
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. OBJECTIVE: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing-remitting MS (RRMS). METHODS: A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed. RESULTS: Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z: -3.82, p<0.001; z: -4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. CONCLUSION: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis.
format Online
Article
Text
id pubmed-9648912
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academia Brasileira de Neurologia -ABNEURO
record_format MEDLINE/PubMed
spelling pubmed-96489122022-12-08 Serum levels of irisin and nesfatin-1 in multiple sclerosis ALTAŞ, Mustafa UCA, Ali Ulvi AKDAĞ, Turan ODABAŞ, Faruk Ömer TOKGÖZ, Osman Serhat Arq Neuropsiquiatr Articles BACKGROUND: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. OBJECTIVE: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing-remitting MS (RRMS). METHODS: A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed. RESULTS: Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z: -3.82, p<0.001; z: -4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. CONCLUSION: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis. Academia Brasileira de Neurologia -ABNEURO 2022-02-06 /pmc/articles/PMC9648912/ /pubmed/35195223 http://dx.doi.org/10.1590/0004-282X-ANP-2020-0520 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Articles
ALTAŞ, Mustafa
UCA, Ali Ulvi
AKDAĞ, Turan
ODABAŞ, Faruk Ömer
TOKGÖZ, Osman Serhat
Serum levels of irisin and nesfatin-1 in multiple sclerosis
title Serum levels of irisin and nesfatin-1 in multiple sclerosis
title_full Serum levels of irisin and nesfatin-1 in multiple sclerosis
title_fullStr Serum levels of irisin and nesfatin-1 in multiple sclerosis
title_full_unstemmed Serum levels of irisin and nesfatin-1 in multiple sclerosis
title_short Serum levels of irisin and nesfatin-1 in multiple sclerosis
title_sort serum levels of irisin and nesfatin-1 in multiple sclerosis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648912/
https://www.ncbi.nlm.nih.gov/pubmed/35195223
http://dx.doi.org/10.1590/0004-282X-ANP-2020-0520
work_keys_str_mv AT altasmustafa serumlevelsofirisinandnesfatin1inmultiplesclerosis
AT ucaaliulvi serumlevelsofirisinandnesfatin1inmultiplesclerosis
AT akdagturan serumlevelsofirisinandnesfatin1inmultiplesclerosis
AT odabasfarukomer serumlevelsofirisinandnesfatin1inmultiplesclerosis
AT tokgozosmanserhat serumlevelsofirisinandnesfatin1inmultiplesclerosis